Alex Shimura Yamashita et al., 2025: Yamashita et al. test mebendazole with radiotherapy in an IDH-mutant glioma model, reporting reduced proliferation, more apoptosis and longer survival for the combination.
An IDH-mutant xenograft model subjected to mebendazole plus RT showed improved survival compared to either therapy alone.
Alex Shimura Yamashita et al., 2025: Yamashita et al. test mebendazole with radiotherapy in an IDH-mutant glioma model, reporting reduced proliferation, more apoptosis and longer survival for the combination. Study type: patient-derived IDH-mutant glioma cells plus orthotopic xenograft. N: not stated in the abstract. Country: USA (Johns Hopkins). Dose: 'nanomolar concentrations' in vitro; in vivo dose not stated in the abstract text captured. Funder: US NIH R01 CA190223. Declared conflicts: 'G.J.R. is an inventor of intellectual property for mebendazole oncology use formulations managed by Johns Hopkins… and discloses a financial interest with licensee…'. Comparator: radiotherapy alone and mebendazole alone. Study type: animal.
